Does Spravato Work for Depression? Esketamine Effectiveness

Esketamine for depression — the active ingredient in Spravato — has been through more formal FDA review than any other ketamine-related treatment on the market. It's the only ketamine-derived medicine with an actual drug-approval label rather than an off-label use, and that label has been expanded twice since Spravato first reached patients in 2019, most recently to allow it as a stand-alone treatment. This guide covers what the trial evidence behind Spravato actually shows, how its three approvals differ, what a labeled dosing schedule looks like, and where it fits against IV ketamine and other options. For depression evidence across ketamine formats more broadly, see does ketamine therapy work for depression. Spravato for depression is now available under three different label configurations, and knowing which one applies to your situation changes what a prescriber can actually offer you.

What Spravato Is FDA-Approved to Treat

Spravato's label has grown in three steps, and each one covers a specific, narrower population than "depression" in general:

• 2019 — treatment-resistant depression, as an add-on.The original approval covers adults with treatment-resistant depression (depression that hasn't adequately improved after two or more antidepressant trials), used together with a daily oral antidepressant, not in place of one.
• 2020 — depressive symptoms with acute suicidal thoughts, as an add-on. A second approval covers adults with major depressive disorder who have acute suicidal ideation or behavior, again alongside comprehensive standard-of-care treatment rather than as a stand-alone option. The label is specific that Spravato has not been shown to prevent suicide or reduce suicidal thoughts on its own — the approval is for improvement in depressive symptoms in this population, a distinction worth understanding rather than glossing over.
• 2025 — treatment-resistant depression, as a stand-alone treatment. In January 2025, the FDA expanded the original indication again, clearing Spravato as a monotherapy for treatment-resistant depression — meaning it no longer has to be paired with a daily oral antidepressant for patients using it this way. This is the first time any medication for treatment-resistant depression has been approved to be used entirely on its own.

Esketamine is a Schedule III controlled substance, and every dose — under any of these three approvals — is administered at a REMS-certified clinic under direct observation, never dispensed for home use. Which approval applies to you also determines whether Spravato can be your only medication or has to be combined with a daily oral antidepressant, so it's worth clarifying with a prescriber before treatment starts, not after.

How Esketamine Is Thought to Work

Esketamine is one of two mirror-image molecules that make up ketamine, isolated and delivered as its own nasal-spray formulation. Like ketamine generally, it's thought to act primarily by blocking NMDA glutamate receptors in the brain — a different target than the serotonin and norepinephrine systems most oral antidepressants act on. That different mechanism is the leading explanation for why esketamine can shift mood within hours to days rather than the four to six weeks typical of standard antidepressants, and it's part of why the approval trials measured response at day 28 rather than the longer windows used for SSRI studies. This is a brief summary of the pharmacology, not the full picture — esketamine's receptor profile differs somewhat from generic, racemic ketamine's, which is one reason the two aren't simply interchangeable despite coming from the same parent molecule.

What the Clinical Trials Actually Showed

The 2019 treatment-resistant depression approval rested on three short-term trials — TRANSFORM-1, TRANSFORM-2, and TRANSFORM-3 — each comparing esketamine plus a new oral antidepressant against placebo nasal spray plus a new oral antidepressant, measured on a standard depression-severity scale (the Montgomery-Åsberg Depression Rating Scale, or MADRS) over 28 days. Only TRANSFORM-2 hit statistical significance on its own. TRANSFORM-1 and TRANSFORM-3 (the latter in older adults) showed a similar direction of benefit but didn't clear that bar individually. Rather than resting on one trial, the FDA approval also drew on SUSTAIN-1, a longer randomized withdrawal study: patients who'd already responded to esketamine were split into groups that either continued dosing or were switched to placebo, and those who continued esketamine relapsed at a meaningfully lower rate. That combination — one strong short-term result plus solid longer-term relapse-prevention data — is what the approval was built on, not a single clean trial across the board.

The 2020 approval for depressive symptoms with suicidal ideation drew on two identical trials, ASPIRE I and ASPIRE II, which enrolled adults in active suicidal crisis — a population most antidepressant trials exclude outright. Both trials showed esketamine plus standard care improved depressive symptoms faster than standard care alone. As Spravato's own label states plainly, though, neither trial was designed or powered to show that esketamine reduces suicidal thoughts or behavior itself; the measured benefit is in depressive symptoms.

The 2025 monotherapy approval is backed by a newer, dedicated trial (often referenced by its internal designation, TRD4005): a placebo-controlled study of esketamine given twice weekly for four weeks with no oral antidepressant added at all. At four weeks, roughly three times as many patients on esketamine monotherapy reached remission as on placebo. That's a real, cited trial result — not a marketing figure — and it's worth reading the honest caveat alongside it: it's one trial measuring a four-week window, not a claim about years of outcomes.

Read together, three separate data points — one statistically significant acute trial, a positive longer-term relapse-prevention trial, and a positive monotherapy trial six years later — describe a treatment with real, replicated evidence behind it across more than one study design, rather than a single result the field is still trying to reproduce.

Esketamine Dosing: What the Treatment Schedule Looks Like

The labeled schedule follows the same general shape whether Spravato is used alongside an antidepressant or as the 2025 monotherapy option, though the exact plan a prescriber sets varies by patient:

• Day 1: a starting dose of 56mg.
• Induction phase (roughly weeks 1–4): twice-weekly dosing at 56mg or 84mg, with the dose adjusted based on response and tolerability.
• Maintenance phase (roughly weeks 5–8): dosing steps down to once weekly.
• Ongoing maintenance (week 9 onward): dosing spaces out further, to once every one to two weeks, based on how durable the response is.

This is the general schedule described in Spravato's label, not instructions for self-administering a dose — every session happens under a clinician's direct supervision, and the specific frequency, dose, and pace of tapering is something your prescriber sets and adjusts for you.

Who Spravato Fits Best

Spravato's clearest fit is a patient whose diagnosis matches one of its label indications — treatment-resistant depression, with or without an oral antidepressant, or depressive symptoms with acute suicidal thoughts alongside standard care — and who has access to a REMS-certified clinic. Patients who are self-paying, want finer real-time dose control, or are being treated for a condition outside Spravato's label (such as chronic pain) more often lean toward IV ketamine instead. For the full side-by-side on cost, dosing control, and scheduling, see IV ketamine vs. Spravato. Many patients don't have to choose permanently — some start with whichever option their insurance and diagnosis favor and revisit the decision with their prescriber later.

A full history matters for either option. A prescriber typically reviews prior antidepressant trials in detail, along with cardiovascular history, any personal history of psychosis, and current substance use, before recommending Spravato or IV ketamine — reasons that can rule either format out entirely aren't unique to one over the other. Patients managing bipolar depression alongside major depressive episodes should flag that history explicitly, since mood-switch risk is a consideration regardless of which ketamine-based option a prescriber is weighing.

Why Insurance Often Favors Spravato

Because Spravato went through the FDA's drug-approval process and is billed as an in-office administered medication with a formal REMS monitoring structure, insurers already have a framework for handling prior authorization and coverage — something generic, off-label IV ketamine typically lacks. That doesn't mean coverage is automatic; plans still vary, prior authorization is usually required, and criteria often ask for documented treatment-resistant depression history — much of the same documentation a prescriber already needs to confirm eligibility for the medication itself, and what Spravato costs and how coverage works in practice often comes down to which specific plan and prior-authorization criteria apply to you. See does insurance cover ketamine therapy for how that process typically works and what to ask a clinic before booking.

What Happens If Spravato Doesn't Work

Not every patient who starts Spravato reaches remission, and a lack of response after a full induction series is useful clinical information rather than a dead end. A prescriber will typically reassess the dose, confirm the diagnosis actually meets the treatment-resistant definition the label targets, and rule out factors — an untreated co-occurring condition, inconsistent dosing, or a medical issue — that could be blunting the response. From there, options include adjusting the maintenance schedule, adding or changing therapy alongside it, trying IV ketamine instead, or exploring a different antidepressant class entirely. Some patients also find the dissociative effects difficult to tolerate even when the medication is working, which is its own reason to have that conversation with a prescriber rather than stopping treatment on your own. It also helps to separate a true non-response from an incomplete trial: skipping or significantly delaying doses during the induction phase can blunt the cumulative effect Spravato is designed to build, so a prescriber will usually confirm the full schedule was actually completed before concluding the medication itself isn't working.

Safety, Monitoring, and Finding a Provider

Every Spravato session includes a required observation period and specific monitoring tied to its boxed warning, separate from generic ketamine's side-effect profile. For the full breakdown of common side effects, the two-hour observation window, the driving restriction, and who should use extra caution, see Spravato side effects: what to expect. That page also covers how to confirm a clinic's REMS certification before booking a first appointment. Because dosing only happens in a certified setting, comparing a few REMS-certified clinics on scheduling flexibility and total visit time is a reasonable step before committing to one.

Ready to compare providers? Browse clinics offering Spravato or search for ketamine clinics in your area to find a REMS-certified provider near you.

Frequently Asked Questions

Sources: FDA prescribing information and approval history for Spravato (esketamine), including the TRANSFORM, SUSTAIN, ASPIRE, and monotherapy trial programs. Informational only — not medical advice. Talk with a licensed clinician about your specific diagnosis and history before starting treatment.